United States· US:0310-4611_08bd9074-9b1b-4737-a313-ac1339dbbeb3
IMFINZI
A durvalumab product containing durvalumab, registered in United States by AstraZeneca Pharmaceuticals LP. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Durvalumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF03 (durvalumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Durvalumab · ATC L01FF03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of durvalumab costs, country by country.
Normalised to the WHO defined daily dose (53.6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Durvalumab · price per daily dose (53.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$274.31
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DURVALUMAB
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Country
- United States (US)
- ATC code
- L01FF03
- ATC class
- Durvalumab
- Defined daily dose
- 53.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 6, 2026
Packs & prices · 1
- ndc110310-4611-50
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for durvalumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Durvalumab · interactions on record
82 records
- 30 severe
- 45 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Durvalumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainIMFINZI 50 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONAstrazeneca Ab
- FinlandImfinzi2care4 ApS
- BelgiumImfinzi 50 mg/mlAstraZeneca
- SwitzerlandImfinzi
- CzechiaIMFINZIAstraZeneca AB, Södertälje
- United KingdomImfinzi 120mg/2.4ml concentrate for solution for infusion vialsAstraZeneca UK Ltd
- Japanデュルバルマブ（遺伝子組換え）アストラゼネカ
- IrelandIMFINZI 50 mg/ml concentrate for solution for infusion.AstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imfinzi
- Liechtenstein · Imfinzi
- Norway · Imfinzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c7fa6ac0-c8ae-47ce-92e2-ea62b5b6c7b8 GET /v1/drugs/c7fa6ac0-c8ae-47ce-92e2-ea62b5b6c7b8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "500",
"substance": "DURVALUMAB",
"productndc": "0310-4611",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/10mL",
"application_number": "BLA761069",
"marketing_category": "BLA"
}See everything about durvalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.